MannKind is betting that more people will choose inhaled medicine for diabetes and lung disease, and that new uses for its products could speed up growth faster than many expect. The upside comes with big hurdles, from insurers pushing back on pricing to doctors and patients being slow to switch, plus tough competition from newer treatments.Read more
MannKind is trying to turn its inhaled insulin from a niche product into a broader option by expanding overseas, adding new patient groups, and stepping up marketing and sales. The bigger upside comes from new inhaled medicines in development and steady royalty income, but slow doctor adoption, heavy dependence on a few products, and rising competition could still hold progress back.Read more
MannKind rides big trends like rising diabetes needs and demand for needle-free options, but slow insurance coverage and low doctor awareness keep Afrezza from spreading quickly. With much of the business tied to just a couple of products and bigger drugmakers circling the same markets, the path to steadier profits may take longer than many expect.Read more
No trending discussion available.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
